Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

Chunxia Qiao; Meiyun Hu; Leiming Guo; Ming Lv; Zhou Lin; Jing Geng; Xiaoling Lang; Xinying Li; Yan Li; Yuanfang Ma; Jiannan Feng; Beifen Shen

doi:10.1186/1471-2172-13-40

Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

BMC Immunology ◽

10.1186/1471-2172-13-40 ◽

2012 ◽

Vol 13 (1) ◽

pp. 40

Author(s):

Chunxia Qiao ◽

Meiyun Hu ◽

Leiming Guo ◽

Ming Lv ◽

Zhou Lin ◽

...

Keyword(s):

Monoclonal Antibody ◽

Complex Formation ◽

Death Receptor ◽

Structural Basis ◽

Death Receptor 5

Download Full-text

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/cbr.2009.0673 ◽

2010 ◽

Vol 25 (1) ◽

pp. 13-19 ◽

Cited By ~ 103

Author(s):

Andres Forero-Torres ◽

Jatin Shah ◽

Tina Wood ◽

James Posey ◽

Ronda Carlisle ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Phase I Trial ◽

Death Receptor ◽

Death Receptor 5 ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-14-2780 ◽

2015 ◽

Vol 21 (12) ◽

pp. 2722-2729 ◽

Cited By ~ 27

Author(s):

Andres Forero-Torres ◽

Katherine E. Varley ◽

Vandana G. Abramson ◽

Yufeng Li ◽

Christos Vaklavas ◽

...

Keyword(s):

Breast Cancer ◽

Monoclonal Antibody ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Death Receptor ◽

Death Receptor 5

Download Full-text

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3537 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3537-3537 ◽

Cited By ~ 18

Author(s):

M. N. Saleh ◽

I. Percent ◽

T. E. Wood ◽

J. Posey ◽

J. Shah ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Death Receptor ◽

Advanced Solid Tumors ◽

Death Receptor 5 ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

240 Molecular imaging of Death Receptor 5 (DR5) occupancy in-vivo by humanized monoclonal antibody CS-1008

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)71945-5 ◽

2010 ◽

Vol 8 (7) ◽

pp. 78

Author(s):

A.M. Scott ◽

F.T. Lee ◽

G.C. Cartwright ◽

G.J. O'Keefe ◽

R.A. Beckman ◽

...

Keyword(s):

Monoclonal Antibody ◽

Molecular Imaging ◽

Death Receptor ◽

Death Receptor 5 ◽

Humanized Monoclonal Antibody

Download Full-text

Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors

Expert Opinion on Biological Therapy ◽

10.1517/14712598.8.8.1167 ◽

2008 ◽

Vol 8 (8) ◽

pp. 1167-1176 ◽

Cited By ~ 37

Author(s):

D Ross Camidge

Keyword(s):

Monoclonal Antibody ◽

Solid Tumors ◽

Death Receptor ◽

Trail Receptor ◽

Death Receptor 5

Download Full-text

Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults

Expert Opinion on Biological Therapy ◽

10.1517/14712598.2011.610788 ◽

2011 ◽

Vol 11 (11) ◽

pp. 1519-1524 ◽

Cited By ~ 6

Author(s):

Madhuri Bajaj ◽

Elisabeth I Heath

Keyword(s):

Monoclonal Antibody ◽

Death Receptor ◽

Death Receptor 5 ◽

Advanced Malignancies

Download Full-text

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.09.053 ◽

2006 ◽

Vol 101 (1) ◽

pp. 46-54 ◽

Cited By ~ 31

Author(s):

J. Michael Straughn ◽

Patsy G. Oliver ◽

Tong Zhou ◽

Wenquan Wang ◽

Ronald D. Alvarez ◽

...

Keyword(s):

Cervical Cancer ◽

Monoclonal Antibody ◽

Radiation Therapy ◽

Death Receptor ◽

Death Receptor 5 ◽

Cancer Model ◽

Anti Tumor Activity

Download Full-text

TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps128 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS128-TPS128 ◽

Cited By ~ 1

Author(s):

A. Forero-Torres ◽

N. U. Lin ◽

M. C. Liu ◽

H. S. Rugo ◽

S. Puhalla ◽

...

Keyword(s):

Breast Cancer ◽

Monoclonal Antibody ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Death Receptor ◽

Death Receptor 5 ◽

Open Label ◽

Randomized Phase Ii

Download Full-text

Knockdown of c-FLIPL enhanced AD5-10 anti-death receptor 5 monoclonal antibody-induced apoptosis in human lung cancer cells

Cancer Science ◽

10.1111/j.1349-7006.2009.01119.x ◽

2009 ◽

Vol 100 (5) ◽

pp. 940-947 ◽

Cited By ~ 7

Author(s):

Feng Chen ◽

Juntang Guo ◽

Yaxi Zhang ◽

Yu Zhao ◽

Naikang Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Monoclonal Antibody ◽

Cancer Cells ◽

Human Lung ◽

Death Receptor ◽

Lung Cancer Cells ◽

Human Lung Cancer ◽

Death Receptor 5 ◽

Human Lung Cancer Cells ◽

Induced Apoptosis

Download Full-text

A Novel Agonistic Anti-Human Death Receptor 5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase- and Mitochondrial-Dependent Apoptosis in Human Leukemia Jurkat Cells

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/cbr.2010.0827 ◽

2011 ◽

Vol 26 (2) ◽

pp. 143-152 ◽

Cited By ~ 5

Author(s):

Yao-wu Du ◽

Ju-gao Chen ◽

Hui-ling Bai ◽

Hong-ying Huang ◽

Jing Wang ◽

...

Keyword(s):

Monoclonal Antibody ◽

Death Receptor ◽

Jurkat Cells ◽

Human Leukemia ◽

Death Receptor 5 ◽

Tumoricidal Activity ◽

Human Death

Download Full-text